Article ; Online: Dolutegravir based therapy showed CD4
2024 Volume 14, Issue 1, Page(s) 3297
Abstract: Recently, dolutegravir (DTG)-based combined therapy, a more effective and safer first-line antiretroviral therapy (ART), has been recommended by the World Health Organization for the treatment of Human Immunodeficiency Virus (HIV) since July 2018. ... ...
Abstract | Recently, dolutegravir (DTG)-based combined therapy, a more effective and safer first-line antiretroviral therapy (ART), has been recommended by the World Health Organization for the treatment of Human Immunodeficiency Virus (HIV) since July 2018. However, its effectiveness in CD4 |
---|---|
MeSH term(s) | Humans ; Acquired Immunodeficiency Syndrome/drug therapy ; Antiretroviral Therapy, Highly Active ; HIV Infections ; Prospective Studies ; Viral Load ; Pilot Projects ; CD4 Lymphocyte Count ; Anti-HIV Agents/pharmacology ; HIV-1/genetics ; CD4-Positive T-Lymphocytes ; RNA/pharmacology ; Heterocyclic Compounds, 3-Ring ; Oxazines ; Piperazines ; Pyridones |
Chemical Substances | dolutegravir (DKO1W9H7M1) ; Anti-HIV Agents ; RNA (63231-63-0) ; Heterocyclic Compounds, 3-Ring ; Oxazines ; Piperazines ; Pyridones |
Language | English |
Publishing date | 2024-02-08 |
Publishing country | England |
Document type | Journal Article |
ZDB-ID | 2615211-3 |
ISSN | 2045-2322 ; 2045-2322 |
ISSN (online) | 2045-2322 |
ISSN | 2045-2322 |
DOI | 10.1038/s41598-024-53282-y |
Database | MEDical Literature Analysis and Retrieval System OnLINE |
More links
Kategorien
Order via subito
This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.